Dr. Grey AI

Lanreotide (Somatuline)

Peptide

Lanreotide is a long-acting synthetic octapeptide analog of somatostatin, FDA-approved for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The landmark CLARINET trial demonstrated 53% reduction in disease progression risk in metastatic GEP-NETs. Available as an extended-release depot formulation (Somatuline Depot) for once-monthly injection.

Quick Answer

What it is

Lanreotide is a long-acting synthetic octapeptide analog of somatostatin, FDA-approved for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The landmark CLARINET trial demonstrated 53% reduction in disease progression risk in metastatic GEP-NETs.

Key findings

  • Grade A: Progression-Free Survival (NETs) (Neuroendocrine Tumors)
  • Grade A: Tumor Stabilization (NETs) (Neuroendocrine Tumors)
  • Grade A: Carcinoid Syndrome Symptoms (Neuroendocrine Tumors)

Safety

  • The landmark CLARINET trial demonstrated 53% reduction in disease progression risk in metastatic GEP-NETs.
  • CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001).
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Lanreotide (Somatuline)

Quick Facts: Lanreotide (Somatuline)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:14
  • Grade A Findings:7
  • Grade B Findings:4
  • Key Effect:Neuroendocrine Tumors
A7
B4
C2
D1
2 conditions · 14 outcomes

Detailed Outcomes

|
A
Progression-Free Survival (NETs)
CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001). 65.1% vs 33.0% PFS at 24 months. Median PFS not reached vs 18 months placebo.
large↑Improves
A
Tumor Stabilization (NETs)
Stable disease rates of 15-89% in clinical trials. Phase II studies show significant antitumor effects with disease control in majority of patients.
large↑Improves
A
Carcinoid Syndrome Symptoms
FDA-approved for symptomatic control of flushing and diarrhea associated with carcinoid syndrome. Significant QOL improvement in symptomatic patients.
large↓Improves
A
VIPoma Symptoms
Effective for controlling watery diarrhea and electrolyte disturbances in VIP-secreting tumors.
large↓Improves
A
GH Suppression (Acromegaly)
50-60% of patients achieve GH control (<2.5 ng/mL) with long-term lanreotide treatment. FDA-approved for acromegaly.
large↓Improves
A
IGF-1 Normalization
Approximately 50% of acromegaly patients achieve IGF-1 normalization with lanreotide depot treatment.
large↓Worsens
A
Acromegaly Symptoms
Significant improvement in soft tissue swelling, headaches, joint pain, and fatigue associated with acromegaly.
moderate↓Improves
B
Anti-Cancer Activity
33 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
9 human trials support this finding. Human clinical trial data available.
moderate↑Improves
B
Pulmonary Function
5 human trials support this finding. Human clinical trial data available.
small↑Improves
B
Liver Protection
5 human trials support this finding. Human clinical trial data available.
small↑Improves
C
GI Protection
4 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Blood Glucose Control
3 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↓Improves
D
Kidney Function
2 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (50)

Lanreotide protects against LPS-induced inflammation in endothelial cells and mouse lungs.
(2025)
PMID: 40241488
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
(2025)
PMID: 40437077
Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.
(2025)
PMID: 40468101
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
(2024)
PMID: 38206830
An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
(2024)
PMID: 38847075
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
(2023)
PMID: 38098114
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
(2023)
PMID: 36044870
The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.
(2022)
PMID: 35587448
Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.
(2021)
PMID: 34664531
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
(2020)
PMID: 32366244

Related Peptides

Octreotide (Sandostatin)

Peptide

2 shared conditions · 13 outcomes

Octreotide is a synthetic octapeptide analog of somatostatin with prolonged action. FDA-approved in 1988, it is available as immediate-release injection and long-acting repeatable (LAR) formulation. Primary indications include acromegaly, carcinoid syndrome, and neuroendocrine tumors. The PROMID trial demonstrated significant antiproliferative effects in midgut neuroendocrine tumors, and multiple trials confirm efficacy for GH/IGF-1 suppression in acromegaly.

Pegvisomant (Somavert)

Peptide

1 shared condition · 10 outcomes

Pegvisomant is a genetically modified growth hormone analog that functions as a GH receptor antagonist. FDA-approved in 2003, it is the first and only GH receptor antagonist for acromegaly. It is indicated for patients with inadequate response to surgery, radiation, or somatostatin analogs. Phase III trials showed up to 97% of patients achieving IGF-1 normalization with long-term treatment, making it the most effective medical therapy for biochemical control.

Pasireotide (Signifor)

Peptide

1 shared condition · 10 outcomes

Pasireotide is a novel multi-receptor-targeted somatostatin analog with high affinity for somatostatin receptor subtypes 1, 2, 3, and 5. FDA-approved in 2012, it is the first pituitary-directed medication for Cushing's disease. Available as twice-daily subcutaneous injection (Signifor) and long-acting monthly injection (Signifor LAR) for acromegaly. The Phase III PASPORT trial demonstrated significant urinary free cortisol normalization in Cushing's disease patients.

Lutetium-177 Dotatate (Lutathera)

Peptide

1 shared condition · 10 outcomes

Lutetium-177 dotatate is a radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT). FDA-approved 2018 for SSTR-positive GEP-NETs. NETTER-1 Phase 3: 65.2% PFS at 20 months vs 10.8% control. 79% reduction in disease progression/death risk. Median OS 48 months vs 36.3 months. First radiopharmaceutical for NETs.